Results 21 to 30 of about 1,693 (197)

Atosiban versus betamimetics in the treatment of preterm labour in Germany: an economic evaluation

BMC Pregnancy and Childbirth, 2009
Background The use of tocolytics is central in delaying birth; however, therapeutic options vary in effectiveness and adverse events profiles, which in turn could have consequences for medical resource use and cost of treatment. Betamimetics are commonly
Connolly Mark, Wex Jaro, Rath Werner
doaj   +2 more sources

Bryophyllum pinnatum enhances the inhibitory effect of atosiban and nifedipine on human myometrial contractility: an in vitro study

BMC Complementary and Alternative Medicine, 2019
Background The herbal medicine Bryophyllum pinnatum has been used as a tocolytic agent in anthroposophic medicine and, recently, in conventional settings alone or as an add-on medication with tocolytic agents such as atosiban or nifedipine.
S. Santos, C. Haslinger, M. Mennet, U. von Mandach, M. Hamburger, A. P. Simões-Wüst   +5 more
doaj   +2 more sources

ATOSIBAN, PERSPECTIVAS SOBRE EL MANEJO ETIOLOGICO DEL PARTO PREMATURO

Revista Chilena de Obstetricia y Ginecología, 2002
Analizamos la información disponible respecto del fármaco tocolítico atosiban para evaluar las ventajas y desventajas de esta droga en comparación con las drogas de primera línea, en cuanto a su acción inhibitoria rápida de las contracciones uterinas, su
Verónica Sáez R., Alfredo M. Germain, Jorge A. Carvajal   +2 more
doaj   +2 more sources

Critical appraisal and clinical utility of atosiban in the management of preterm labor

Therapeutics and Clinical Risk Management, 2010
Olaleye Sanu1, Ronald F Lamont1–51Department of Obstetrics and Gynaecology, St Mary’s Imperial NHS Trust, London, UK; 2Northwick Park Institute of Medical Research, London, UK; 3Imperial College, London, UK; 4University College ...
Olaleye Sanu, Ronald F Lamont
doaj   +1 more source

Pregnancy and neonatal outcomes of hyperglycemia caused by atosiban administration during pregnancy

Clinical and Experimental Obstetrics & Gynecology, 2021
It is known that atosiban has fewer side effects than conventional tocolytics. In clinical practice, however, hyperglycemia can be commonly observed in mothers who have been administered atosiban.
Hyun Jin Ko, Seong Yeon Hong, Jin Young Bae   +2 more
doaj   +1 more source

Atosiban application in fresh ET cycle is effective for women undergoing repeated embryo implantation failures, especially for advanced-age obese patients

Scientific Reports, 2023
To assess the effect of atosiban in pregnancy outcomes of the fresh embryo transfer (ET), the retrospective cohort study was conducted. Six hundred and eighty-nine cases (using atosiban) and 1377 age and ET cycle-matched controls were collected from the ...
Jie Li, Sien Mo, Zhong Lin, Qiuling Shi
doaj   +1 more source

Prenatal exposure to antihypertensive medication: A systematic review of neurodevelopmental and educational outcomes. [PDF]

JCPP Adv
This systematic review investigated the association of prenatal exposure to antihypertensive medication with longer‐term poor neurodevelopmental outcomes by evaluating the findings from existing literature. We undertook a systematic review of previous studies looking specifically at neurodevelopmental outcomes in children.
Alkhalaf S, Singh S, Pell JP, Nelson SM, Mackay DF, Fleming M.   +5 more
europepmc   +2 more sources

Efficacy of atosiban for repeated embryo implantation failure: A systematic review and meta-analysis

Frontiers in Endocrinology, 2023
BackgroundRepeated embryo implantation failure (RIF) posed a significant challenge in assisted reproduction. Evidence of its therapeutic effectiveness including atosiban used around embryo transfer to improve pregnancy outcomes in RIF patients undergoing
Ruxin Wang, Ruxin Wang, Haixia Huang, Haixia Huang, Yong Tan, Yong Tan, Guicheng Xia   +6 more
doaj   +1 more source

A prospective case–control trial to evaluate and compare the efficacy and safety of atosiban versus placebo in In vitro Fertilization-embryo transfer program

Journal of Human Reproductive Sciences, 2018
Background: Recent developments in assisted reproductive technology focus on potential advances to improve its success rate. Atosiban, a combined oxytocin/vasopressin V1a receptor antagonist, is a novel class of drug involved in basic priming of the ...
Vineet Mishra, Himani Agarwal, Sugandha Goel, Priyankur Roy, Sumesh Choudhary, Sunita Lamba   +5 more
doaj   +1 more source

School Performance After Maintenance Tocolysis With Nifedipine for Threatened Preterm Birth: 12-Year Follow-Up of the APOSTEL 2 Trial. [PDF]

BJOG
ABSTRACT Objective To evaluate school performance at 12 years of age in children prenatally exposed to maintenance tocolysis with nifedipine versus placebo. Design 12‐year follow‐up of the multicentre APOSTEL 2 trial, in which participants with threatened preterm birth between 26+0 and 32+2 weeks of gestation, who remained pregnant after initial 48‐h ...
van der Windt LI, Meliezer JAL, Pajkrt E, Spaanderman MEA, Scheepers HCJ, Mol BW, Oudijk MA, Ravelli ACJ, Roos C.   +8 more
europepmc   +2 more sources